Table 2.
Chemotherapy agents used in the 30 trials.
| Study | Chemotherapy regimen, doses | No. of cycles |
|---|---|---|
| Shoji et al., 201310 | Carboplatin (AUC6), paclitaxel (175 mg/m2)/ docetaxel (70 mg/m2) | 2 (18 patients) 3 (5 patients) |
| Shen et al., 201211 | Cisplatin (20 mg/m2 D1-4)/carboplatin (AUC5), paclitaxel (150 mg/m2) | 2 |
| Yamaguchi et al., 201212 | Nedaplatin (80 mg/m2), irinotecan (60 mg/m2 D1,8) | 3 |
| Pinheiro et al., 201113 | Mitomycin C (10 mg/m2), methotrexate (300 mg/m2 with folonic acid), bleomycin (15 mg/m2 D1,8) | 4 |
| Vizza et al., 201114 | Cisplatin (75 mg/m2), paclitaxel (175 mg/m2), ifosfamide (5 g/m2, mesna) | 3 |
| Mossa et al., 201015 | Cisplatin (50 mg/m2), vincristine (1 mg/m2), bleomycin (25 mg/m2 D1,8) | 3 |
| Shoji et al., 201016 | Cisplatin (70 mg/m2), irinotecan (70 mg/m2 D1,8) | 2 |
| Cho et al., 200918 | Cisplatin (75 mg/m2)/carboplatin (AUC5), paclitaxel (135 mg/m2) | 2 |
| Kokawa et al., 200719 | Mitomycin-C (10 mg/m2), irinotecan (100 mg/m2) D1,8,15 Out of 28 days cycles |
2 (28 patients) 3 (7 patients) |
| Sláma et al., 200720 | Cisplatin (50 mg/m2), ifosfamide (5 g/m2, mesna) | 3 |
| Eddy et al., 200721 | Cisplatin, vincristine | 3 |
| Choi et al., 200622 | Cisplatin (100 mg/m2), 5-fluorouracil (1000 mg/m2/day D2-5) | 2 |
| Cai et al., 200623 | Cisplatin (100 mg/m2), 5-fluorouracil (1000 mg/m2/day D2-5) | 2 |
| Termrungruanglert et al., 200524 | Cisplatin (70 mg/m2), gemcitabine (1000 mg/m2 D1,8) | 2 |
| Taneja et al., 200525 | Cisplatin (50 mg/m2), bleomycin (15 mg/m2 D1, 2), vincristine (1 mg/m2) | 3 |
| DeSouza et al., 200426 | Cisplatin (60 mg/m2), methotrexate (300 mg/m2 with folonic acid), bleomycin (30 mg/m2 twice weekly) | 3 |
| Huang et al., 200327 | Cisplatin (50 mg/m2), bleomycin (15 mg/m2 D1, 2), vincristine (1 mg/m2) | 3 |
| Napolitano et al., 200328 | Cisplatin (50 mg/m2), bleomycin (15 mg/m2 D1, 2), vincristine (1 mg/m2) | 3 |
| D’Agostino et al., 200229 | Cisplatin (100 mg/m2), epirubicin (100 mg/m2), paclitaxel (175 mg/m2) | 3 |
| Benedetti-Panici et al., 200230 | Cisplatin (80 mg/m2), vincristine (1 mg/m2), bleomycin (25 mg/m2 3 days) | 2 |
| Duenas-Gonzalez et al., 200331 | Carboplatin (AUC 6), paclitaxel (175 mg/m2) | 3 |
| Duenas-Gonzalez et al., 200232 | Cisplatin (100 mg/m2), gemcitabine (1 mg/m2 D1,8) | 3 |
| Costa et al., 200133 | Cisplatin (40 mg/m2), epirubicin(30 mg/m2), etoposide(75 mg/m2), bleomycin (15 mg D1,2) | 3 |
| MacLeod et al., 200134 | Cisplatin (50 mg/m2)/carboplatin (AUC5) based combination | 3 |
| Aoki et al., 200135 | Cisplatin (60 mg/m2), vinblastine (4 mg/m2 D1, 2), bleomycin (25 mg/m2 3 days) | 2 |
| Hwang et al., 200136 | Cisplatin (50 mg/m2), vinblastine (6 mg/m2), bleomycin (25 mg/m2 3 days) | 3 |
| Chang et al., 200037 | Cisplatin (50 mg/m2), vincristine (1 mg/m2), bleomycin (25 mg/m2 for 3 days) | 3 |
| Zanetta et al., 199838 | Cisplatin (50 mg/m2) (75 mg/m2 in 10 patients), paclitaxel (175 mg/m2), ifosfamide (5 g/m2, mesna) | 3 |
| Sardi et al., 199739 | Cisplatin (50 mg/m2), vincristine (1 mg/m2), bleomycin (25 mg/m2 D1-3) | 3 |
| Lacava et al., 199740 | Vinrolbine (30 mg/m2 weekly) | 4 |